Data consistently shows that individuals with mental illness are more likely to smoke than those without, making it crucial to include them in clinical trials related to smoking cessation. Unfortunately, the opposite seems to be true. The commentary, titled "Inequities in smoking cessation clinical trials testing pharmacotherapy: excluding smokers with mental health disorders," aims to examine the practice and reasons behind excluding smokers with mental health disorders from such clinical trials.
A research team has analyzed the Cochrane systematic review database as of September 2020 to obtain evaluations regarding the use of drug therapy for smoking cessation. "We included 279 randomized controlled trials (RCT) from 13 Cochrane reviews. In all studies, 51 (18.3%) explicitly excluded participants with any mental health disorders (MHD), 152 (54.5%) conditionally excluded based on certain MHD criteria, and 76 (27.2%) provided insufficient information to determine inclusion or exclusion. The study found that compared to studies on nicotine replacement therapy, research on using antidepressant medication for smoking cessation was 3.33 times more likely to conditionally exclude smokers with MHD (95% CI 1.38 to 8.01, p=0.007)," the researchers reported.
In fact, their conclusion was that there wasn't enough representation of smokers with MHD in clinical trials examining the safety and efficacy of smoking cessation drugs, but there wasn't enough data collected to explain why. The study emphasized the importance of promoting participation from this minority group in trials.
Psychologically healthy patients find quitting smoking more difficult.
Other studies have also found that individuals with mental health conditions are not only more likely to smoke than those without such conditions, but also have a harder time quitting. As a result, they can greatly benefit from additional support in terms of cessation and access to safer alternatives. This would at least reduce their risk of developing smoking-related illnesses.
However, an article in the Psychiatry Advisor discusses what mental health professionals should keep in mind when using e-cigarettes and warns of dangerous components such as zinc, lead, chromium, manganese, and copper found in various e-cigarette products. Dr. Catherine Striley, Associate Professor and Director of Epidemiology in Psychiatry at the University of Florida, wrote the article and added that while most components in e-liquids can be safely ingested, they may cause harm to the lungs and cardiovascular system.
Statement:
This article is compiled from third-party information and is intended solely for industry exchange and learning.
This article does not reflect the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The translation of this article is intended for industry communication and research purposes.
Due to limitations in translation skills, the translated article may not fully reflect the original text. Please refer to the original article for accuracy.
2FIRSTS fully aligns with the Chinese government's stance on any domestic issues, as well as those involving Hong Kong, Macau, Taiwan, and foreign affairs.
The copyright for compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
